98%
921
2 minutes
20
In the preceding papers, imposing certain complicated and strong conditions, the present author showed that the solution to the BCS-Bogoliubov gap equation in superconductivity is twice differentiable only on the neighborhoods of absolute zero temperature and the transition temperature so as to show that the phase transition is of the second order from the viewpoint of operator theory. Instead, we impose a certain simple and weak condition in this paper, and show that there is a unique nonnegative solution and that the solution is indeed twice differentiable on a closed interval from a certain positive temperature to the transition temperature as well as pointing out several properties of the solution. We then give another operator-theoretical proof for the second-order phase transition in the BCS-Bogoliubov model. Since the thermodynamic potential has the squared solution in its form, we deal with the squared BCS-Bogoliubov gap equation. Here, the potential in the BCS-Bogoliubov gap equation is a function and need not be a constant.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120184 | PMC |
http://dx.doi.org/10.1038/s41598-022-11652-4 | DOI Listing |
J Colloid Interface Sci
September 2025
Key Laboratory of Urban Rail Transit Intelligent Operation and Maintenance Technology & Equipment of Zhejiang Province, College of Engineering, Zhejiang Normal University, Jinhua 321004, China. Electronic address:
Developing high-performance wearable flexible sensors that can adapt well to complex environments has become a hotspot. Herein, a polyvinyl alcohol based composite hydrogel sensor with high mechanical strength, desirable frost/swelling resistance, and highly sensitive sensing performance was proposed by a multi-component collaborative design strategy. Meanwhile, an intelligent gesture recognition system was established by combining machine learning algorithm.
View Article and Find Full Text PDFBlood Adv
September 2025
Alfred Health and Monash University, East Melbourne, Australia.
Zanubrutinib is a next-generation covalent Bruton tyrosine kinase (BTK) inhibitor designed to provide complete and sustained BTK occupancy for efficacy across disease-relevant tissues, with fewer off-target adverse events (AEs) than other covalent BTK inhibitors. In the phase 3 ASPEN study (BGB-3111-302), comparable efficacy and a favorable safety profile versus ibrutinib were demonstrated in patients with MYD88-mutated Waldenström macroglobulinemia (WM), leading to approval of zanubrutinib for patients with WM. BGB-3111-LTE1 (LTE1) is a long-term extension study to which eligible patients, including patients from comparator treatment arms, could enroll following participation in various parent studies of zanubrutinib to treat B-cell malignancies.
View Article and Find Full Text PDFKhirurgiia (Mosk)
September 2025
Mogilev Regional Clinical Hospital, Mogilev, Republic of Belarus.
Objective: To evaluate clinical and laboratory effectiveness of ultrasound treatment for purulent wounds.
Material And Methods: The study enrolled 46 patients with purulent wounds divided into the main group (23 patients, ultrasonic treatment) and the control group (23 patients, traditional treatment). We assessed treatment effectiveness considering visual data, quality of granulation tissue, wound defect area and marginal epithelialization, complete blood count and C-reactive protein.
Climacteric
September 2025
Gynecology Discipline, Obstetrics and Gynecology Department, University of São Paulo School of Medicine, São Paulo, Brazil.
Objective: Social media is an increasingly relevant tool for health education, enabling information exchange, promoting autonomy and supporting informed decision-making. This study introduces Menopausando, a predominantly Portuguese-language digital platform designed to support women during menopausal transition and postmenopause.
Method: This cross-sectional study has been carried out in the Gynecology Discipline, São Paulo University, Brazil, since 2019.
Epilepsia
September 2025
Department of Pharmacology and Neuroscience, Creighton University School of Medicine, Omaha, Nebraska, USA.
The rate of sudden unexpected death in epilepsy (SUDEP) is ~1 per 1000 patients each year. Terminal events reportedly involve repeated and prolonged apnea, suggesting a failure to autoresuscitate. To better understand the mechanisms and identify novel therapeutics, standardized tests to screen for autoresuscitation efficacy are needed in preclinical SUDEP.
View Article and Find Full Text PDF